The treatment landscape for metastatic breast cancer is rapidly evolving. With all of these new advancements and research, it can be helpful to review the available treatment options and best practices for selecting an approach after treatment with a CDK4/6 inhibitor has failed. That’s why Dr. Charles Turck discusses how we can treat patients with metastatic breast cancer in the second- and third-line setting with Dr. Hope Rugo, who’s a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Hellen Diller Family Comprehensive Cancer Center.